Roche Holding AG (OTCMKTS:RHHBY) Receives Average Rating of “Hold” from Brokerages

Roche Holding AG (OTCMKTS:RHHBY – Get Rating) has been given an average recommendation of “Hold” by the twelve research firms that are covering the firm, MarketBeat reports. Two equities research analysts have rated the stock with a sell recommendation, six have issued a hold recommendation and four have given a buy recommendation to the company. The average 1-year price target among analysts that have issued a report on the stock in the last year is $235.00.

A number of brokerages have weighed in on RHHBY. UBS Group lifted their price target on shares of Roche from CHF 328 to CHF 329 and gave the company a “neutral” rating in a report on Wednesday, December 14th. Deutsche Bank Aktiengesellschaft lowered shares of Roche from a “hold” rating to a “sell” rating in a report on Wednesday, January 18th. Societe Generale upgraded shares of Roche from a “hold” rating to a “buy” rating in a report on Monday, February 27th. Jefferies Financial Group lowered shares of Roche from a “buy” rating to a “hold” rating in a report on Wednesday, January 4th. Finally, JPMorgan Chase & Co. lowered shares of Roche from a “neutral” rating to an “underweight” rating in a report on Tuesday, January 3rd.

Roche Price Performance

RHHBY stock opened at $35.07 on Friday. The company has a 50 day moving average price of $37.87 and a two-hundred day moving average price of $39.70. Roche has a one year low of $34.70 and a one year high of $53.86. The company has a quick ratio of 0.80, a current ratio of 1.24 and a debt-to-equity ratio of 0.67.

Roche Increases Dividend

The firm also recently announced a dividend, which will be paid on Monday, March 27th. Investors of record on Friday, March 17th will be issued a dividend of $0.8068 per share. This is a positive change from Roche’s previous dividend of $0.79. The ex-dividend date of this dividend is Thursday, March 16th. This represents a dividend yield of 2.22%.

Hedge Funds Weigh In On Roche

Institutional investors have recently added to or reduced their stakes in the company. Vigilant Capital Management LLC lifted its holdings in Roche by 455.6% in the 3rd quarter. Vigilant Capital Management LLC now owns 2,439 shares of the company’s stock worth $99,000 after buying an additional 2,000 shares in the last quarter. Enterprise Financial Services Corp lifted its holdings in Roche by 8.7% in the 3rd quarter. Enterprise Financial Services Corp now owns 5,408 shares of the company’s stock worth $222,000 after buying an additional 432 shares in the last quarter. FNY Investment Advisers LLC acquired a new position in Roche in the 3rd quarter worth $243,000. Woodstock Corp acquired a new position in Roche in the 4th quarter worth $263,000. Finally, New Hampshire Trust acquired a new position in Roche in the 4th quarter worth $302,000. Institutional investors and hedge funds own 0.28% of the company’s stock.

About Roche

(Get Rating)

Roche Holding AG operates as a research healthcare company. It operates through the following divisions: Pharmaceuticals and Diagnostics. The Pharmaceutical division comprises the business segments, such as Roche Pharmaceuticals and Chuga. The Diagnostic division consists of the following four business areas: centralized and point of care solutions, molecular diagnostics, tissue diagnostics and diabetes care.